학술논문
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.
Document Type
Article
Author
Branche, Angela R; Rouphael, Nadine G; Losada, Cecilia; Baden, Lindsey R; Anderson, Evan J; Luetkemeyer, Anne F; Diemert, David J; Winokur, Patricia L; Presti, Rachel M; Kottkamp, Angelica C; Falsey, Ann R; Frey, Sharon E; Rupp, Richard; Bäcker, Martín; Novak, Richard M; Walter, Emmanuel B; Jackson, Lisa A; Little, Susan J; Immergluck, Lilly C; Mahgoub, Siham M
Source
Subject
*IMMUNOGLOBULIN analysis
*CONFIDENCE intervals
*COVID-19 vaccines
*CORONAVIRUS spike protein
*CHRONIC diseases
*CHEMILUMINESCENCE assay
*VACCINE immunogenicity
*VACCINE effectiveness
*ANTIBODY formation
*RANDOMIZED controlled trials
*MESSENGER RNA
*DESCRIPTIVE statistics
*RESEARCH funding
*STATISTICAL sampling
*POLYMERASE chain reaction
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1058-4838
Abstract
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines. [ABSTRACT FROM AUTHOR]